Share Price | Synaptogenix, Inc. Stock Analysis & Recommendation

Q: How big is Synaptogenix, Inc.?

Market Cap: As of Jun 18, Synaptogenix, Inc. has a market capitalization of 5.45 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Synaptogenix, Inc. reported net sales of 0.00 million and a net profit of -12.17 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.86 million and total assets of 17.73 million.

Q: What does Synaptogenix, Inc. do?

Overview: Synaptogenix, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) Market cap: USD 5.45 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -2.87 Return on Equity: -113.14% Price to Book: 1.05Contact Details: Registrar Address: Not available.

Q: Is Synaptogenix, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Synaptogenix, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, along with weekly Bollinger Bands showing bullish signals. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish outlook. The monthly RSI is bearish, suggesting caution. In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 80.69% compared to the S&P 500's 12.22%, but it has significantly underperformed over the past three years with a return of -96.84% against the S&P 500's 70.41%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

343.18 k

Shareholding (Sep 2025)

FII

0.04%

Held by 5 FIIs

DII

98.75%

Held by 1 DIIs

Promoter

0.05%

How big is Synaptogenix, Inc.?

22-Jun-2025

As of Jun 18, Synaptogenix, Inc. has a market capitalization of 5.45 million, with net sales of 0.00 million and a net profit of -12.17 million over the latest four quarters. The company reported shareholder's funds of 5.86 million and total assets of 17.73 million as of Dec 24.

View full answer

What does Synaptogenix, Inc. do?

22-Jun-2025

Synaptogenix, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of $5.45 million and no recent profits. Key financial metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -113.14%.

View full answer

Is Synaptogenix, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Synaptogenix, Inc. shows a mildly bullish trend with daily moving averages indicating mild bullishness, but caution is advised due to bearish signals from the monthly RSI and mixed indicators from the weekly MACD and KST, despite a strong year-to-date performance of 80.69% compared to the S&P 500's 12.22%.

View full answer

Compare Synaptogenix, Inc. with Similar Stocks

Tempest Therapeutics, Inc.Petros Pharmaceuticals, Inc.Universe Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 48 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-40.86%

Price to Book

2.86

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

16.21%

6 Months

-5.1%

1 Year

108.14%

2 Years

20.81%

3 Years

613.09%

4 Years

-96.4%

5 Years

-97.22%

Synaptogenix, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.89%

EBIT Growth (5y)

6.99%

EBIT to Interest (avg)

-11.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.87

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.58%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.86

EV to EBIT

-4.20

EV to EBITDA

-4.20

EV to Capital Employed

-30.92

EV to Sales

30.92

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-40.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.15%)

Foreign Institutions

Held by 5 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 31.58% vs -812.50% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.40",
          "val2": "-1.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.60",
          "val2": "-4.10",
          "chgp": "36.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.90",
          "val2": "-5.70",
          "chgp": "31.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,862.90%",
          "val2": "0.00%",
          "chgp": "-686.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -113.33% vs -7.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-8.30",
          "chgp": "18.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.60",
          "val2": "0.60",
          "chgp": "-1,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.80",
          "val2": "-6.00",
          "chgp": "-113.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-1.40

Interest

0.00

Exceptional Items

-2.60

-4.10

36.59%

Consolidate Net Profit

-3.90

-5.70

31.58%

Operating Profit Margin (Excl OI)

-6,862.90%

0.00%

-686.29%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 31.58% vs -812.50% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.80

-8.30

18.07%

Interest

0.00

Exceptional Items

-6.60

0.60

-1,200.00%

Consolidate Net Profit

-12.80

-6.00

-113.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -113.33% vs -7.14% in Dec 2023

All Annual Results

Company CV

About Synaptogenix, Inc.

Synaptogenix, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available